NASDAQ · BLFS
Healthcare · Medical - Instruments & Supplies
$34.92
Up+$0.09 (+0.26%)
Updated Sep 11, 2026, 5:03 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BLFS closed at $34.92 after 20 trading sessions, down 0.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $34.62 | $34.95 | $34.38 | $34.92 | 1.36M |
| Sep 9, 2026 | $35.01 | $35.62 | $34.62 | $34.93 | 1.27M |
| Sep 8, 2026 | $35.03 | $36.055 | $35.03 | $35.38 | 788.4K |
| Sep 4, 2026 | $35.07 | $35.52 | $34.89 | $35.25 | 344.31K |
| Sep 3, 2026 | $36.42 | $36.425 | $35.17 | $35.53 | 703.21K |
| Sep 2, 2026 | $35.58 | $36.44 | $35.58 | $35.92 | 967.48K |
| Sep 1, 2026 | $36.98 | $37.25 | $35.12 | $35.47 | 950.36K |
| Aug 31, 2026 | $36.05 | $37.10 | $36.05 | $37.07 | 1.25M |
| Aug 28, 2026 | $37.05 | $37.20 | $36.35 | $36.38 | 1.04M |
| Aug 27, 2026 | $37.07 | $37.39 | $36.99 | $37.20 | 1.22M |
| Aug 26, 2026 | $37.16 | $37.505 | $36.95 | $37.00 | 815.98K |
| Aug 25, 2026 | $37.20 | $37.7675 | $37.01 | $37.22 | 1.38M |
| Aug 24, 2026 | $36.81 | $37.37 | $36.40 | $37.19 | 548.52K |
| Aug 21, 2026 | $36.89 | $37.28 | $36.29 | $37.10 | 750.37K |
| Aug 20, 2026 | $35.77 | $38.10 | $35.77 | $36.97 | 681.73K |
| Aug 19, 2026 | $35.45 | $36.91 | $35.45 | $36.47 | 703.14K |
| Aug 18, 2026 | $35.40 | $35.40 | $34.755 | $34.94 | 390.29K |
| Aug 17, 2026 | $34.77 | $35.46 | $34.7501 | $35.45 | 395.62K |
| Aug 14, 2026 | $35.17 | $35.22 | $34.81 | $35.07 | 478.68K |
| Aug 13, 2026 | $35.00 | $35.34 | $34.415 | $35.23 | 592.53K |
The latest Smart Investors Daily articles mentioning BLFS.
BLFS research
Company profile and research snapshot.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Benchmark | Hold | — |
| Jul 27, 2026 | Stephens & Co. | Equal-Weight | — |
| Jul 23, 2026 | Jefferies | Hold | — |
| Jul 23, 2026 | TD Cowen | Hold | — |
| Jul 22, 2026 | Lake Street | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Small Cap Strategy”. The letter can be downloaded here. The strategy returned 24.01% in the second quarter, outperforming the Russell 2000 Index’s 21.49% return. Performance was positively affected by stock selection in health care and industrials, while the Fund’s underweight position […]
ChartMill · Sep 4, 2026
BIOLIFE SOLUTIONS (BLFS) combines high-growth earnings momentum with a consolidating chart, earning top technical and setup ratings for a breakout.
Benzinga · Aug 10, 2026
Benchmark analyst Robert Wasserman downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold.
SeekingAlpha · Aug 2, 2026
Repligenâs $1.5B BioLife acquisition and strong Q2 results lift guidance, but valuation looks stretched. Click for more on RGEN stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BLFS.
